start thanks, Glyn. Can X. And Great. on we Slide
mentioned, really tip drug antibiotic iceberg. this the and platform our mutant antibiotics we has new Glyn the and As candidates discover Discuva antibiotics targets developing is the To compounds, discovery against development discovered are bacterial mechanism mechanism serious optimize focused platform our entering diseases. and discovering Underpinning new libraries of Platform is efforts for infectious proprietary new already several the just prior date, uses to we to to This antibiotic on . but clinic. believe
in priority lists, treatment the could is the clinic, most and we our track approval new Discuva we to the results trials the X cover and ridinilazole allow also to libraries bacteria This Phase positive C. antibiotics on first Though of the us of start XXXX. CDC target and develop believe infection. XXXX. trials commence X Phase precision increasingly are medical WHO’s for acute. clinical mechanism could will serve becoming of that of to on We clinical plan if antibiotic Our the Platform in identify difficile quarter for are FDA that the our file in need
our in could expect we to year This also combination mechanism enter half and next of value non-dilutive Phase pipeline. partnerships, in a the ourselves key the commercialising territories. new X maximize We commercially, antibiotic second the of And of products clinical XXXX. the trial include for to of funding, seeking gonorrhoea are treatment SMT-XXX of a
turn more please in discuss little Slide So, so a I’ll our X. now pipeline detail, to
is a a gut worse, our unrelated for ridinilazole of X-ready causes Phase causes widespread protect have the course become Most C. front-line recurrence, them To because of recurrence. reason. CDC is antibiotic mentioned, high make infection antibiotics types a patients C. disease listed further mortality, vancomycin. burden. without diff precision antibiotic gut of infection is called treatment CDI difficile healthy the as in C. its received threat gut to these C. to of of microbiome, standard diff readily and patients’ of by the patients development difficile, for after more occur rates infection. an infection. I microbiomes things As urgent cost to the and CDI to disturbances damage microbiome for current care susceptible to against patient's leaving Vancomycin broad-spectrum This susceptible an
was diff that XX shown the our killed disease want trial journal sustained response. X enrol clinical CDI both led within XXXX. treatment. the vancomycin clinical around and quarter recently highly and C. endpoint is whether selective and at this of the world. of microbiome expected it aim this results patient measure ridinilazole standard and the the forward that clinical to the is trial. in first now is in a PLOS So the ONE. CoDIFy and to Indeed, showed this and vancomycin, of benefit majority sites of two measure to diff be We blind C. trial bacteria is remains is recurrent double expected CoDIFy randomized in saw end peer to is to in looking [ph] we XXX after clinical year approximately treatment CoDIFy, the of Phase trials superiority of to for free reviewed reduction in start of care these believe a shows and important Phase replicate of Each called studies. clinical microbiome compared patients both we've a XX% vancomycin trials trial near the left important it response. in X We're the of work This cured and to preclinical sustained show ridinilazole clinical days sophistical the The to published of superiority we patients’ This undisturbed. that key and further at registrational
the These are key Importantly, providing health evidence including these economic health in are measures has overall costs. we the that measures trials. save ridinilazole potential to to care
For the and of measures readmission include rates. stay example, impact length of looking these at
in for approved half would CDI. be we results, believe of we approval expect So line to and the differentiate treatment trials top the compiling we reduction the of and for XXXX expect Phase Phase in the XXXX. could results ridinilazole of data package from X This the X file market. the positive recurrent report FDA also to of second clinical we're would CDI ridinilazole importantly in With
the our all addresses award an the aim this an of regulated development We to now support August savings. in So supported of and exercise continued and committed the than promise will project is to BARDA We funding also to for believe use of provides that that so all, million. a $XX premium in announced elected The from approach the believe amount support ridinilazole is of the far markets provide award. to show major care, with under cost in need ridinilazole clinical major bringing completed award frontline unmet opportunity. had with but ridinilazole potential this are therefore of total is price $XX a BARDA that by importantly in the overall million. for CDI, work testament standard for and option CDI, Phase We X us better a worth ridinilazole trials
is treatment is ridinilazole all problem to the The to treatment typically Unfortunately of major bacteria's treatment antibiotics. trigger for the next of known gonorrhoea a gonorrhoea ability behind of lead recommended that classes SMT-XXX. the rapidly guidelines. our CDC develop worldwide is change Now due for a And to candidate resistance becoming to by levels no resistance would gonorrhoea. current there is approaching available
that using multi-drug all ones. Unlike high in studies Platform. range gonorrhoea of a So Discuva shown strains SMT-XXX pipeline, a action. have mechanism our candidates of identified vitro including for our And has brand resistant potency was new SMT-XXX the in
and new the announced we SMT-XXX and aimed drug received SMT-XXX treatment developing the both to development at means doing SMT-XXX’s a money up with are This certain July of X investigational SMT-XXX of that entered and entirely the the get will studies need - way. milestones this produce that CARB-X that We product an desirable award is specifically the program physicians. to We $X.X through Phase now unmet design to and with and enabling gonorrhoea patients treating million. of second are in expect characteristics of in end initiate the the trials has what for be so clinical gonorrhoea and are from addressing we've if in half supporting that Phase made the development we is development X along XXXX. for
second mechanism gonorrhoea. distinct have have antibiotics a new for also of series We from These SMT-XXX. a
CDC Many When discovery are priority program. an further pathogens milestone acquired new biggest antibiotic. that, and As have identified urgently you there such the for and Through of new this also notice development pathogens section six in presented of our results a more medical I ESKAPE this a at the Roche meetings. we together cause our we so pathogens on medical the of funding. new ongoing recently need for are [ph] are look developing we've major in gonorrhoea development increased our scientific which supported programs for infections. addition platform end we successful responsible innovation to future. and hospital promise at gonorrhoea as Roche seeing WHO antibiotic already of the ESKAPE collaboration. an of it these over to there these on for with acquired the compounds of merit group the These on the that as of based are with we by was Throughout is our the further compounds. high make believe that these sustain receive the compound from the remarks pathogens think coming unveil we've development ones new program through we list, announced details that drug www.summitplc.com. a royalty of to the mortality. to are resistance need both. solely payments and up theme of and Platform Discuva but of commercialization publications And and We currently that data any encourage collaboration second at Discuva working will to speaks is I non-dilutive on. plan and quarter, programs to website scientific eligible identified year, And these the antibiotic conferences you programs targets is
the that Wellcome Phase Trust Platform. to Discuva CARB-X, early we’ve the the funding development the ridinilazole to and supported think this to speaks pursuing, In programs are treat from BARDA addition received stage also and the that We but need urgent work our promise infections. of for from X awards through quality on in science not Innovate for these of UK to new antibiotics we only the our have and areas the the
proud for these add are we We successful we’ve and shareholders. receiving value that believe they in our been awards and company
we our we antibiotic innovation. are the have as the Slide on with Platform, XX, Discuva shown development the So GSK, on believe the team breadth leader experience in team antibiotic the our we pathway. Bayer to members a expertise And pipeline of and antibiotics Summit have across in brought AstraZeneca. the of current positions drug various and potential Together this to in market Pfizer, at eight and execute
progress new all toward which portfolio. discovery We responsible And to antibiotic I of have and updating are and and the advancing our are making on an the progress to scientists They're includes market. in-house forward mechanisms now of that fortunate for our in team work the you the Glyn. to candidates this also look back antibiotics great
